Pneumococcal |
Update on the use of pneumococcal vaccines in adults 65 years of age and older – Pneumococcal vaccines |
2018 |
Varicella |
Updated Recommendations on the Use of Herpes Zoster Vaccines
|
2018 |
Pertussis, Tetanus and Diphtheria |
Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine |
2018 |
Pertussis, Tetanus and Diphtheria |
Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness |
2018 |
Bacille Calmette Guérin (BCG) |
Statement on Bacille Calmette Guérin (BCG) Vaccine - Erratum (2005) |
2004 |
Cholear Implant Recipients |
Immunization Recommendations for Cochlear Implant Recipients |
2003 |
Haemophilus Influenzae Type B |
Statement on the recommended use of pentavalent and hexavalent vaccines |
2007 |
Haemophilus Influenzae Type B |
Interchangeability of Diphtheria, Tetanus, Acellular Pertussis, Polio, haemophilus Influenzae Type B Combination Vaccines Presently Approved for Use in Canada for Children < 7 Years of Age |
2005 |
Hepatitis |
Update on the recommended use of Hepatitis B vaccine |
2017 |
Hepatitis |
Update on the Recommended use of Hepatitis A Vaccine |
2016 |
Hepatitis |
Statement on the recommended use of pentavalent and hexavalent vaccines |
2007 |
Hepatitis |
Update on hepatitis A vaccine (AVAXIM®, Aventis Pasteur) |
2001 |
Hepatitis |
Statement on Alternate Adolescent Schedule for Hepatitis B Vaccine |
2000 |
Hepatitis |
Supplementary Statement on Hepatitis A Vaccine |
2000 |
Hepatitis |
Supplementary statement on hepatitis prevention - hepatitis A and hepatitis B combination vaccine for children |
1999 |
Hepatitis |
Statement on combination vaccines against hepatitis A and hepatitis B |
1999 |
Human Papillomavirus |
Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations |
2017 |
Human Papillomavirus |
NACI Literature Review for HPV Immunization of Immunocompromised Populations |
2017 |
Human Papillomavirus |
Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule |
2016 |
Human Papillomavirus |
Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule
Amendment to the 2015 "Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule" |
2015 |
Human Papillomavirus |
Update on Human Papillomavirus (HPV) Vaccines |
2012 |
Human Papillomavirus |
Statement on Human Papillomavirus Vaccine |
2007 |
Human Papillomavirus |
Literature review on HPV 6, 11, 16 and 18: Disease and Vaccine Characteristics |
2007 |
Immunization |
Evidence-based recommendations for immunization - Methods of the National Advisory Committee on Immunization |
2009 |
Influenza |
Literature Review on the Comparative Effectiveness and Immunogenicity of Subunit and Split Virus Inactivated Influenza Vaccines in Adults 65 Years of Age |
2018 |
Influenza |
Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2018-2019
|
2018 |
Influenza |
Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017–2018
|
2017 |
Influenza |
National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016-2017
|
2016 |
Influenza |
Literature Review of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older |
2016 |
Influenza |
Literature Review on Pediatric Fluad® Influenza Vaccine Use in Children 6-72 Months of Age |
2015 |
Influenza |
National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2015-2016 |
2015 |
Influenza |
Opinion on Live Attenuated Influenza Vaccine (LAIV) Effectiveness in Young Children |
2015 |
Influenza |
Influenza Vaccine Effectiveness, Immunogenicity, and Safety in Healthy Adults 19-64 Years Old |
2014 |
Influenza |
Literature Review on Influenza Vaccination in Healthy 5-18-Year-Olds |
2014 |
Influenza |
Literature Review on Quadrivalent Influenza Vaccines |
2014 |
Influenza |
Statement on Seasonal Influenza Vaccine for 2014-2015 |
2014 |
Influenza |
Statement on Seasonal Influenza Vaccine for 2013-2014
Revised Wording to the National Advisory Committee on Immunization (NACI) Recommendation for Live Attenuated Influenza Vaccine (LAIV) in Healthy Children and Adolescents 2-17 Years of Age |
2013 |
Influenza |
Statement on Seasonal Influenza Vaccine for 2012-2013 |
2012 |
Influenza |
Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 |
2011 |
Influenza |
Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 |
2011 |
Influenza |
Statement on Seasonal Influenza Vaccine for 2011-2012 |
2011 |
Influenza |
Addendum to the 2010-2011 Seasonal Trivalent Inactivated Influenza Vaccine |
2011 |
Influenza |
Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011 |
2010 |
Influenza |
Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2009-2010 |
2009 |
Influenza |
Statement on Influenza Vaccination for the 2008-2009 Season |
2008 |
Influenza |
Statement on Influenza Vaccination for the 2007-2008 Season |
2007 |
Influenza |
Statement on Influenza Vaccination for the 2006-2007 Season |
2006 |
Influenza |
Update on Influenza Vaccination for the 2005-2006 Season |
2006 |
Influenza |
Statement on Influenza Vaccination for the 2005-2006 Season |
2005 |
Influenza |
Statement on Influenza Vaccination for the 2004-2005 Season |
2004 |
Influenza |
Statement on Influenza Vaccination for the 2003-2004 Season |
2003 |
Influenza |
Supplementary Statement for the 2002-2003 Influenza Season: Update on Oculo-respiratory Syndrome in Association with Influenza Vaccination |
2002 |
Influenza |
Statement on Influenza Vaccination for the 2002-2003 Season |
2002 |
Influenza |
Supplementary Statement for the 2001-2002 Season: Influenza Vaccination of Persons Who Experienced Oculo-Respiratory Syndrome Following Previous Influenza Vaccination (ACS-7) |
2001 |
Influenza |
Statement on Influenza Vaccination for the 2001-2002 Season (ACS-4) |
2001 |
Influenza |
Supplementary statement on influenza vaccination: continued use of Fluviral® influenza vaccine in the 2000-2001 season (ACS-1) |
2001 |
Influenza |
Statement on Influenza Vaccination for the 2000-2001 Season |
2000 |
Measles |
Statement on Measles-Mumps-Rubella-Varicella Vaccine |
2010 |
Measles |
Measles Surveillance: Guidelines for Laboratory Support |
1998 |
Measles |
Interim Advisory on Measles Revaccination of Persons with Acquired Immunodeficiency Syndrome (AIDS) |
1996 |
Measles |
Supplementary Statement on Measles Elimination in Canada |
1996 |
Measles |
Guidelines for Control of Measles Outbreaks in Canada |
1995 |
Measles |
Updated NACI recommendations for measles post-exposure prophylaxis |
2018 |
Meningococcal Disease |
Update on Quadrivalent Meningococcal Vaccines available in Canada |
2015 |
Meningococcal Disease |
Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine |
2014 |
Meningococcal Disease |
Literature review on serogroup B invasive meningococcal disease: epidemiology, multicomponent meningococcal B vaccine characteristics and other factors for consideration |
2014 |
Meningococcal Disease |
Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine |
2014 |
Meningococcal Disease |
Update on the Use of Quadrivalent Conjugate Meningococcal Vaccines |
2013 |
Meningococcal Disease |
Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations |
2009 |
Meningococcal Disease |
Meningococcal C Conjugate for Infants statement |
2007 |
Meningococcal Disease |
Statement on Conjugate Meningococcal Vaccine for Serogroups A,C, Y and W135 |
2007 |
Meningococcal Disease |
Update on Meningococcal C Conjugate Vaccines |
2005 |
Meningococcal Disease |
Supplementary Statement on Conjugate Meningococcal Vaccines |
2003 |
Meningococcal Disease |
Statement on Recommended Use of Meningococcal Vaccines
|
2001 |
MMR (Measles, Mumps, Rubella) |
Supplementary Statement on MMR Vaccine and Anaphylactic Hypersensitivity to Egg or Egg-Related Antigens |
1996 |
MMRV (Measles, Mumps, Rubella, Varicella) |
Statement on Measles-Mumps-Rubella-Varicella Vaccine |
2010 |
MMRV (Measles, Mumps, Rubella, Varicella, Febrile Seizures) |
Update on Measles-Mumps-Rubella-Varicella Vaccine and Febrile Seizures |
2016 |
Mumps |
Statement on Measles-Mumps-Rubella-Varicella Vaccine |
2010 |
Mumps |
Guidelines for the Prevention and Control of Mumps Outbreaks in Canada |
2010 |
Mumps |
Statement on Mumps Vaccine |
2007 |
Pertussis, Tetanus, and Diphtheria |
Update on Pertussis Vaccination in Pregnancy |
2014 |
Pertussis, Tetanus, and Diphtheria |
Statement on the Booster for 4-6 year-olds for Protection against Pertussis |
2014 |
Pertussis, Tetanus, and Diphtheria |
Statement on the recommended use of pentavalent and hexavalent vaccines |
2007 |
Pertussis, Tetanus, and Diphtheria |
Literature review on DTaP based penta- and hexavalent vaccines approved for clinical use in Canada |
2006 |
Pertussis, Tetanus, and Diphtheria |
Interval Between Administration of Vaccines Against Diphtheria, Tetanus, and Pertussis |
2005 |
Pertussis, Tetanus, and Diphtheria |
Interchangeability of Diphtheria, Tetanus, Acellular Pertussis, Polio, Haemophilus Influenzae Type B Combination Vaccines Presently Approved for Use in Canada for Children < 7 Years of Age |
2005 |
Pertussis, Tetanus, and Diphtheria |
Clarification - Prevention of Pertussis in Adolescents and Adults |
2004 |
Pertussis, Tetanus, and Diphtheria |
Prevention of Pertussis in Adolescents and Adults |
2003 |
Pertussis, Tetanus, and Diphtheria |
Statement on Adult/Adolescent Formulation of Combined Acellular Pertussis, Tetanus, and Diphtheria Vaccine |
2000 |
Pneumococcus |
Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation |
2016 |
Pneumococcus |
Re-Immunization with Polysaccharide 23-Valent Pneumococcal Vaccine (Pneu-P-23) |
2015 |
Pneumococcus |
Update on the Use of Pneumococcal Vaccines: Addition of Asthma as a High-Risk Condition |
2014 |
Pneumococcus |
Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13) |
2013 |
Pneumococcus |
Update on the Use of Conjugate Pneumococcal Vaccines in Childhood |
2010 |
Pneumococcus |
Update on Pediatric Invasive Pneumococcal Disease and Recommended Use of Conjugate Pneumococcal Vaccines |
2010 |
Pneumococcus |
Statement on the recommended use of pneumococcal 23-valent polysaccharide vaccine in homeless persons and injection drug users |
2008 |
Pneumococcus |
Update On the Recommendations For The Routine Use of Pneumococcal Conjugate Vaccine For Infants |
2006 |
Pneumococcus |
Recommendations for use of Pneumococcal 23-Valent Polysaccharide Vaccine During Shortage |
2004 |
Pneumococcus |
Statement on the Recommended Use of Pneumococcal Conjugate Vaccine: Addendum |
2003 |
Pneumococcus |
Statement On Recommended Use Of Pneumococcal Conjugate Vaccine |
2002 |
Poliomyelitis |
Statement on the recommended use of pentavalent and hexavalent vaccines |
2007 |
Poliomyelitis |
Interchangeability of Diphtheria, Tetanus, Acellular Pertussis, Polio, haemophilus Influenzae Type B Combination Vaccines Presently Approved for Use in Canada for Children < 7 Years of Age |
2005 |
Rabies Vaccines |
Recommendations Regarding the Management of Bat Exposures to Prevent Human Rabies |
2009 |
Rabies Vaccines |
Update on Rabies Vaccines |
2005 |
Respiratory Syncytial Virus (RSV) |
Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab) |
2003 |
Rotavirus |
Statement on Rotavirus Vaccines and Intussusception |
2016 |
Rotavirus |
Literature Review on Rotavirus: Disease and Vaccine Characteristics |
2010 |
Rotavirus |
Updated Statement on the use of Rotavirus Vaccines |
2010 |
Rotavirus |
Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine |
2008 |
Rubella |
Statement on Measles-Mumps-Rubella-Varicella Vaccine |
2010 |
Smallpox |
Statement on Smallpox Vaccination |
2002 |
Thimerosal in Vaccines |
Thimerosal: Updated Statement |
2007 |
Thimerosal in Vaccines |
Updated Recommendations on the use of Thimerosal-Containing Vaccines in Canada |
2005 |
Thimerosal in Vaccines |
Statement on Thimerosal |
2003 |
Thimerosal in Vaccines |
Thimerosal in Vaccines |
1999 |
Varicella |
Updated recommendations for the use of varicella zoster immune globulin (VarIg) for the prevention of varicella in at-risk patients |
2016 |
Varicella |
Varicella Proof of Immunity - 2015 Update |
2015 |
Varicella |
Update on the Use of Herpes Zoster Vaccine |
2014 |
Varicella |
Literature Review on One-Dose and Two-Dose Varicella Vaccination |
2010 |
Varicella |
Statement on Measles-Mumps-Rubella-Varicella Vaccine |
2010 |
Varicella |
Varicella Vaccination Two-Dose Recommendations. |
2010 |
Varicella |
Updated Recommendations For The Use Of Varicella And MMR Vaccines In HIV-infected Individuals |
2010 |
Varicella |
Statement on the Recommended Use of Herpes Zoster Vaccine |
2010 |
Varicella |
Varizig™ as the varicella zoster immune globulin for the prevention of varicella In at-risk patients |
2006 |
Varicella |
Update on Varicella |
2004 |
Varicella |
NACI Update to Statement on Varicella Vaccine |
2002 |
Varicella |
Statement on Recommended Use of Varicella Virus Vaccine |
1999 |